Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Elxleben – page 3

438 clinical trials in Elxleben, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Elxleben at a glance
438
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

438 trials in Elxleben

Open in trial search

Study of ELA026 for Treatment of Secondary Hemophagocytic Lymphohistiocytosis in Patients with Lymphoma Who Have Not Received Previous Treatment

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:ELA026
  • Sponsor:Electra Therapeutics Inc.

Study on Bortezomib and Drug Combination for Children with High-Risk Relapsed Acute Lymphoblastic Leukemia (ALL)

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Bortezomib
  • Sponsor:Charite Universitaetsmedizin Berlin KöR

Study on the Safety and Effectiveness of EIK1001 and Pembrolizumab for Patients with Advanced Melanoma

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Eikon Therapeutics Inc.

Study on the Effects of Baricitinib and Drug Combination for Adults with Severe Community-Acquired Pneumonia, Severe Influenza, or Severe and Moderate COVID-19

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Amoxicillin Sodium
  • Sponsor:Universitair Medisch Centrum Utrecht

Cardiac failure

Recruiting

Study on the Effects of Finerenone in Patients with Heart Failure and Preserved Ejection Fraction Hospitalized for Acute Decompensated Heart Failure

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Finerenone
  • Sponsor:Colorado Prevention Center

Efficacy and Safety of RO7568282 in Adults with Early Symptomatic Alzheimer’s Disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Phase 3 Study of GSK6042981 versus Imatinib in Adults with Previously Untreated Metastatic or Unresectable Gastrointestinal Stromal Tumors (GIST)

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Imatinib Mesilate
  • Sponsor:Glaxosmithkline Research & Development Limited

Long-Term Safety Study of Asciminib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Bosutinib
  • Sponsor:Novartis Pharma AG

Phase 3 Study of Enfortumab Vedotin plus Pembrolizumab in Adults with Muscle‑Invasive Bladder Cancer Ineligible for Cystectomy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Enfortumab Vedotin
  • Sponsor:Pfizer Inc.

Study of LY3537982, pembrolizumab, and a drug combination for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Eli Lilly & Co.

Safety and Efficacy of Efimosfermin Alfa vs Placebo in Adults with Alcohol-Related Liver Disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Efimosfermin alfa
  • Sponsor:Glaxosmithkline Research & Development Limited

A study of the safety and efficacy of AC01 in patients with heart failure with reduced ejection fraction

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Drocamorelin
  • Sponsor:AnaCardio AB

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Elxleben

What the registry says about research in the country

01 Breast Cancer Research

Innovative clinical research focusing on advanced breast cancer treatment, specifically targeting HER2-negative and hormone receptor-positive cases. This comprehensive study examines treatment efficacy and resistance patterns.

  • Treatment Response Analysis
  • Survival Rate Assessment
  • Progression Monitoring

The research aims to evaluate patient outcomes through detailed analysis of progression-free survival and overall survival rates, providing valuable insights into treatment effectiveness for advanced breast cancer cases.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.